rs1553704446
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_001457.4(FLNB):c.5072G>A(p.Gly1691Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1691C) has been classified as Pathogenic.
Frequency
Consequence
NM_001457.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FLNB | NM_001457.4 | c.5072G>A | p.Gly1691Asp | missense_variant | 29/46 | ENST00000295956.9 | NP_001448.2 | |
FLNB | NM_001164317.2 | c.5165G>A | p.Gly1722Asp | missense_variant | 30/47 | NP_001157789.1 | ||
FLNB | NM_001164318.2 | c.5072G>A | p.Gly1691Asp | missense_variant | 29/46 | NP_001157790.1 | ||
FLNB | NM_001164319.2 | c.5072G>A | p.Gly1691Asp | missense_variant | 29/45 | NP_001157791.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FLNB | ENST00000295956.9 | c.5072G>A | p.Gly1691Asp | missense_variant | 29/46 | 1 | NM_001457.4 | ENSP00000295956.5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Abnormality of the skeletal system Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 04, 2021 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly1691 amino acid residue in FLNB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 14991055, 16648377, 16752402, 27048506). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FLNB protein function. This variant has been observed in individual(s) with autosomal dominant Larsen syndrome (PMID: 22190451). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 522782). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with aspartic acid at codon 1691 of the FLNB protein (p.Gly1691Asp). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and aspartic acid. - |
Larsen syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | May 03, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at